23andMe Holding Co. (ME)
| Market Cap | 64.92M |
| Revenue (ttm) | 208.78M |
| Net Income (ttm) | -390.37M |
| Shares Out | 26.83M |
| EPS (ttm) | -15.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,880 |
| Open | 2.730 |
| Previous Close | 2.740 |
| Day's Range | 2.420 - 2.842 |
| 52-Week Range | 2.420 - 13.740 |
| Beta | 1.15 |
| Analysts | Hold |
| Price Target | 9.40 (+288.43%) |
| Earnings Date | Jan 28, 2025 |
About ME
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how... [Read more]
Financial Performance
In 2023, 23andMe Holding Co.'s revenue was $219.64 million, a decrease of -26.66% compared to the previous year's $299.49 million. Losses were -$666.70 million, 113.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ME stock is "Hold" and the 12-month stock price forecast is $9.4.
News
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity valu...
23andMe Launches New Genetic Report on Osteoporosis
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variants Provides 23andMe+ Premium members with insight into their likelih...
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.
23andMe Special Committee Announces Exploration of Strategic Alternatives
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics company ...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges
23andMe Reportedly Considers Selling Lemonaid Telehealth Unit
23andMe is reportedly considering the sale of Lemonaid Health, its telehealth operation. The consumer genetic testing kit company acquired Lemonaid in 2021 for $400 million and is now weighing a sale,...
23andMe has been quietly exploring a possible sale of its telehealth business, Lemonaid
23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million.
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology
23andMe is helping collaborators better understand disease biology, identify novel targets, boost clinical trial success, and engage people in their care 23andMe is helping collaborators better unders...
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation...
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
23andMe Holding Co. (NASDAQ:ME) Q2 2025 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Katie Watson - Vice President, Communications Anne Wojcicki - Chief Executive Office...
23andMe cuts 40% of staff in restructuring
23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its th...
What's happening with 23andMe? Mass layoffs and restructuring are the latest blow for the embattled DNA testing company
DNA-testing company 23andMe (Nasdaq: ME), once an industry leader that attracted millions of customers, including rapper Snoop Dogg and investor Warren Buffett, has announced significant cuts to its o...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The embattled genetic testing company said Monday that it's cutting about 200 jobs, or ab...
Genetic testing firm 23andMe cuts 40% of its workforce amid financial struggles
Company says it will cut about 200 employees as value plummets in aftermath of huge data breach
23andMe's stock turns lower after company posts its latest quarterly loss
Stock had gained late Monday on news it would cut 40% of its workforce as part of a restructuring.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe cuts 40% of its workforce
Genetic testing firm 23andMe said on Monday it is reducing its overall headcount by over 200 employees or about 40% of the workforce, as part of a restructuring program.
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-hou...
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the secon...
23andMe to Report Q2 FY2025 Financial Results
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial r...
23andMe Regains Compliance With Nasdaq Listing Requirements
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the Com...
23andMe appoints new board members as it works to stem the company's slide
23andMe said it appointed three new independent directors to its board on Monday. All seven of 23andMe's previous directors resigned in September over its "strategic direction.
23andMe appoints three new board members following abrupt resignations
23andMe appointed three new independent directors to its board, the company said Tuesday. The announcement comes about a month after all seven of 23andMe's previous independent directors abruptly resi...